Andrii Yalanskyi / Shutterstock.com

22 February 2024FeaturesBiotechnologyJens Petry and Tom Gassmann, Squire Patton Boggs

Dispute resolution in Asian biotech joint ventures: things to consider

Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Pfizer and Basilea extend Cresemba licence agreement to Asia-Pacific

7 December 2017 Basilea Pharmaceutica and Pfizer have reached a deal for a licence agreement for the antifungal medication Cresemba to cover China and 16 countries in the Asia-Pacific region.

Asia

Aslan: fighting cancer head-on

1 November 2017 Based in Singapore, biotech company Aslan Pharmaceuticals specialises in developing new treatments to fight cancers that are prevalent in Asia, often requiring licensing deals to ensure it is fully equipped. LSIPR spoke to general counsel Ben Goodger to find out more.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Killing the golden goose of US drug innovation (Part I): Follow the money

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

The flaw that landed Sanofi a win in the rare disease space

Roche resolves cancer test dispute with Stanford affiliated startup

Dispute resolution in Asian biotech joint ventures: things to consider

More on this story

Editor's picks

Editor's picks

More features